MediWound Ltd. (MDWD)
Nasdaq · Healthcare · Biotechnology
$13.51−0.07%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $174M
- 52-week range
- $12.52 – $20.03
- 52-week change
- −22.92%
- EPS (trailing)
- −$2.17
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 19, 2026
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Headquarters: Yavne, Israel · 121 employees · mediwound.com